Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
September 2016
in “JCI insight”
TLDR Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
In a study conducted from July 2014 to March 2015, 66 patients with alopecia areata (AA), including alopecia totalis (AT) and alopecia universalis (AU), were treated with 5 mg of tofacitinib citrate twice daily for 3 months. The study found that 64% of patients responded to treatment, with 32% achieving a 50% or greater improvement in their Severity of Alopecia Tool (SALT) score. AA and ophiasis subtypes had a better response compared to AT and AU subtypes. A negative correlation was observed between the duration of AA and the percentage change in SALT score. Adverse events were mostly mild infections. The study concluded that tofacitinib is a safe and effective treatment for severe AA, but the effects were not long-lasting, with hair loss recurring approximately 2 months after treatment cessation. Additionally, molecular profiling was used to predict treatment response, with gene expression signatures differentiating between true nonresponders, slow responders, and true responders. Safety monitoring revealed one case of elevated liver enzymes and average increases in cholesterol levels.
View this study on insight.jci.org →
Cited in this study
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Interventions for alopecia areata
Current treatments for alopecia show no significant long-term benefits.
research Familial aggregation of alopecia areata
Alopecia areata, a common autoimmune hair loss condition, often runs in families.
Related
research Resistant alopecia areata treated with tofacitinib
Tofacitinib can be effective in treating hair loss caused by alopecia areata.
research Trichoscopy in alopecia areata
Trichoscopy shows black dots, yellow dots, and empty follicles are common in Alopecia Areata, with broken and exclamation mark hair as typical patterns.
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
research Dermoscopic evaluation of therapeutic response to intralesional triamcinolone acetonide in the treatment of Alopecia areata
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Extensive alopecia areata: Not necessarily recalcitrant to therapy!
Some people with severe, long-lasting baldness responded well to a specific combination treatment.